BVF
Latest statistics and disclosures from BVF's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, KYMR, RVMD, MIRM, TYRA, and represent 50.56% of BVF's stock portfolio.
- Added to shares of these 10 stocks: FDMT (+$37M), XNCR (+$17M), AVTX (+$9.1M), AXSM (+$8.2M), IDYA (+$7.8M), CDTX, ACIU, TENX, Nls Pharmaceutics, Forte Biosciences.
- Started 5 new stock positions in Nls Pharmaceutics, Forte Biosciences, AVTX, TENX, XNCR.
- Reduced shares in these 10 stocks: RVMD (-$114M), MRUS (-$76M), IONS (-$70M), PTGX (-$66M), CGON (-$54M), MIRM (-$51M), Calliditas Therap Adr Rep 2 Ord (-$29M), ROIV (-$29M), JANX (-$19M), ZYME (-$16M).
- Sold out of its positions in ASLN, Calliditas Therap Adr Rep 2 Ord, FBRX, JANX, RZLT, UNCY, VIRX, ROIV, NLSP, MRUS.
- BVF was a net seller of stock by $-470M.
- BVF has $3.4B in assets under management (AUM), dropping by -4.19%.
- Central Index Key (CIK): 0001056807
Tip: Access up to 7 years of quarterly data
Positions held by BVF consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BVF
BVF holds 55 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 32.1 | $1.1B | 22M | 50.42 |
|
|
| Kymera Therapeutics (KYMR) | 7.1 | $244M | 5.2M | 47.33 |
|
|
| Revolution Medicines (RVMD) | 4.6 | $158M | -41% | 3.5M | 45.35 |
|
| Mirum Pharmaceuticals (MIRM) | 3.5 | $120M | -29% | 3.1M | 39.00 |
|
| Tyra Biosciences (TYRA) | 3.2 | $110M | 4.7M | 23.51 |
|
|
| Olema Pharmaceuticals (OLMA) | 3.2 | $109M | 9.1M | 11.94 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.9 | $98M | -9% | 2.2M | 43.89 |
|
| Cullinan Oncology (CGEM) | 2.8 | $96M | 5.8M | 16.74 |
|
|
| Xoma Royalty Corporation Com New (XOMA) | 2.8 | $96M | 3.6M | 26.48 |
|
|
| Axsome Therapeutics (AXSM) | 2.7 | $94M | +9% | 1.0M | 89.87 |
|
| Protagonist Therapeutics (PTGX) | 2.4 | $83M | -44% | 1.9M | 45.00 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $80M | +88% | 7.4M | 10.81 |
|
| Ac Immune Sa SHS (ACIU) | 2.2 | $74M | +3% | 20M | 3.78 |
|
| Gh Research Ordinary Shares (GHRS) | 2.0 | $70M | 10M | 6.69 |
|
|
| Kura Oncology (KURA) | 1.9 | $66M | -17% | 3.4M | 19.54 |
|
| Third Harmonic Bio (THRD) | 1.7 | $59M | 4.4M | 13.55 |
|
|
| Ionis Pharmaceuticals (IONS) | 1.7 | $58M | -54% | 1.5M | 40.06 |
|
| Zymeworks Del (ZYME) | 1.7 | $58M | -21% | 4.6M | 12.55 |
|
| Essa Pharma Com New (EPIX) | 1.6 | $53M | 8.7M | 6.06 |
|
|
| Agios Pharmaceuticals (AGIO) | 1.5 | $53M | 1.2M | 44.43 |
|
|
| Celcuity (CELC) | 1.5 | $52M | 3.5M | 14.91 |
|
|
| 89bio (ETNB) | 1.5 | $50M | -10% | 6.8M | 7.40 |
|
| Foghorn Therapeutics (FHTX) | 1.4 | $49M | 5.3M | 9.31 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 1.3 | $45M | 1.6M | 28.79 |
|
|
| Ideaya Biosciences (IDYA) | 1.3 | $45M | +21% | 1.4M | 31.68 |
|
| Annexon (ANNX) | 1.2 | $41M | 7.0M | 5.92 |
|
|
| Cg Oncology (CGON) | 1.1 | $38M | -58% | 995k | 37.73 |
|
| Repare Therapeutics Ord (RPTX) | 1.0 | $36M | 10M | 3.44 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.7 | $25M | 1.5M | 16.60 |
|
|
| Xencor (XNCR) | 0.5 | $17M | NEW | 850k | 20.11 |
|
| Eledon Pharmaceuticals (ELDN) | 0.5 | $16M | 6.3M | 2.49 |
|
|
| Tscan Therapeutics (TCRX) | 0.4 | $15M | 3.0M | 4.98 |
|
|
| Engene Holdings (ENGN) | 0.4 | $15M | 2.3M | 6.60 |
|
|
| Immunic (IMUX) | 0.4 | $15M | 8.9M | 1.65 |
|
|
| Allakos (ALLK) | 0.3 | $11M | 17M | 0.65 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $9.1M | NEW | 967k | 9.46 |
|
| Ikena Oncology (IKNA) | 0.2 | $8.3M | 4.8M | 1.73 |
|
|
| Cidara Therapeutics Com New (CDTX) | 0.2 | $7.6M | +104% | 703k | 10.75 |
|
| Cytomx Therapeutics (CTMX) | 0.2 | $6.2M | 5.2M | 1.18 |
|
|
| Vigil Neuroscience (VIGL) | 0.2 | $6.2M | 1.8M | 3.40 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.2 | $6.0M | 2.0M | 3.01 |
|
|
| Verastem Com New (VSTM) | 0.1 | $5.0M | 1.7M | 2.99 |
|
|
| Ovid Therapeutics (OVID) | 0.1 | $4.5M | 3.9M | 1.18 |
|
|
| Pieris Pharmaceuticals Com New (PIRS) | 0.1 | $4.3M | 258k | 16.74 |
|
|
| Verve Therapeutics (VERV) | 0.1 | $3.1M | 650k | 4.84 |
|
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $2.5M | 918k | 2.70 |
|
|
| Molecular Partners Ads (MOLN) | 0.1 | $2.1M | 443k | 4.82 |
|
|
| Elevation Oncology (ELEV) | 0.1 | $1.8M | +28% | 3.0M | 0.60 |
|
| Glycomimetics (GLYC) | 0.0 | $1.6M | 9.5M | 0.17 |
|
|
| Inventiva Sa Ads (IVA) | 0.0 | $1.3M | 686k | 1.85 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $1.2M | NEW | 340k | 3.46 |
|
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.0 | $804k | 945k | 0.85 |
|
|
| Molecular Templates Com New (MTEM) | 0.0 | $734k | 522k | 1.41 |
|
|
| Nls Pharmaceutics Com New | 0.0 | $728k | NEW | 144k | 5.07 |
|
| Forte Biosciences Com New | 0.0 | $668k | NEW | 119k | 5.60 |
|
Past Filings by BVF
SEC 13F filings are viewable for BVF going back to 2010
- BVF 2024 Q3 filed Nov. 14, 2024
- BVF 2024 Q2 filed Aug. 14, 2024
- BVF 2024 Q1 filed May 15, 2024
- BVF 2023 Q4 filed Feb. 14, 2024
- BVF 2023 Q3 filed Nov. 14, 2023
- BVF 2023 Q2 filed Aug. 14, 2023
- BVF 2023 Q1 filed May 15, 2023
- BVF 2022 Q4 filed Feb. 14, 2023
- BVF 2022 Q3 filed Nov. 14, 2022
- BVF 2022 Q2 filed Aug. 15, 2022
- BVF 2022 Q1 filed May 16, 2022
- BVF 2021 Q4 filed Feb. 14, 2022
- BVF 2021 Q3 filed Nov. 15, 2021
- BVF 2021 Q2 filed Aug. 16, 2021
- BVF 2021 Q1 filed May 17, 2021
- BVF 2020 Q4 filed Feb. 12, 2021